About hemo
About HEMO
HEMO BIOENGINEERING LIMITED (the “Company” and collectively with its subsidiaries, “HEMO”) is committed to developing and providing innovative interventional medical devices to patients to improve their health and quality of life.
We have built a suite of interventional medical devices targeting peripheral and neuro-vascular diseases.
Our portfolio of neuro-interventional medical devices covers all of the ischemic stroke, hemorrhagic stroke and neuro access fields.
Hemo's headquarter is in Singapore. We have corporate, R&D and production operations in Singapore, US, Malaysia and China, and are constantly expanding. We also work with a network of key opinion leaders and industry experts. Hemo is founded by Chairman Professor Jack Wang, an industry veteran and seasoned entrepreneur who had previously served as CEO at both SGX Mainboard-listed Biosensors International Group and JW Medical Systems.
OUR MISSION
We are committed to developing and providing innovative interventional medical devices to patients to improve their health and quality of life.
CORPORATE MILESTONES
– Our Company was incorporated
– In-licensed technologies for our aspiration catheter and access catheter
– Raised a total of US$27 million from our Series A financing
– Commenced clinical trial for our aspiration catheter based on more than 200 patients
– Obtained approval for our FocusLine® balloon dilation catheter
– Raised approximately US$11.5 million from our Series A+ financing
– Obtained approval for our access catheter and commercialized the product in certain markets
– Commenced clinical trial for our stent retriever
– Raised a total of US$50 million from our Series B financing
– Obtained approval for our FocuStar® neuro balloon catheter – Rx
– Raised US$50 million from our Series C financing
– Managed to enter a major market China with our aspiration accessory and commercialized the products
– Commercialized our FocuStar® neuro balloon catheter – Rx
– Became the first Asian company to obtain approval for our aspiration catheter and Mountix micro catheter and commercialized the products in China
– Obtained approval for FlexStar™ balloon guiding catheter
– Initiated clinical trial for our neuro drug-coated balloon for the treatment of intracranial atherosclerosis patients
